Background: Current drug therapy of atherosclerosis is focused on treatment of major risk factors, e.g. hypercholesterolemia while in the future direct disease modifi cation might provide additional benefi ts. However, development of medicines targeting vascular wall disease is complicated by the lack of reliable biomarkers. In this study, we took a novel approach to identify circulating biomarkers indicative of drug effi cacy by reducing the complexity of the in vivo system to the level where neither disease progression nor drug treatment was associated with the changes in plasma cholesterol.
Introduction
Current drug therapy of atherosclerosis is focused on treatment of major risk factors, e.g. hypercholesterolemia while in the future direct disease modifi cation might provide additional benefi ts. 1, 2 However, discovery and development of medicines targeting vascular wall disease (and hence not inducing any changes of plasma lipids) is complicated by the lack of reliable biomarkers. 2, 3 Recent clinical data suggest detrimental cumulative cardiovascular effects of several compounds that improve atherosclerosis risk factors. 4, 5 Therefore, early indication of pro-atherogenic drug activities would be desired. To date, vascular imaging remains the only available option. 3 However, it is expensive and, for some techniques, invasive, that limits its application on a large scale.
Is it possible to fi nd a circulating non-lipid marker that would refl ect drug-induced changes in atherosclerotic plaques? In the clinic, correlation between markers of infl ammation and risk of cardiovascular events is established. 6 However, it is unknown whether any of those markers refl ects drug-induced changes in the plaque size.
In ApoE-defi cient mice, genetically determined hypercholesterolemia leads to development of atherosclerotic lesions. 7 Importantly, the lesions develop progressively over time while plasma cholesterol levels stay constant. 8 Therefore, this model provides an opportunity to focus on circulating markers that would be associated with the changes in the plaque size but not in plasma cholesterol. Apparently, this approach is limited by multiple confounding factors such as age and systemic infl ammation. However, mere separation of plasma cholesterol and vascular drug effects represents the fi rst important step in unraveling very complex interactions between drug effects and potential blood markers. It has been previously reported that angiotensin-II converting enzyme inhibitor ramipril(Ram) signifi cantly reduced atherosclerotic burden ApoE-/-mice and HMG-CoA reductase inhibitor simvastatin(Sim) paradoxically increased lesion size. [9] [10] [11] [12] In this paper, we decided to exploit this phenomenon and seek circulating markers of cholesterol-independent, drug-induced vascular changes in ApoE-defi cient mice. Blood and vascular samples were obtained from the same animals for histology, blood chemistry, blood RNA and protein assessments. The changes in blood chemistry, RNA and protein were correlated with changes in vascular histology.
Materials and Methods

Animal experiments
All activities were conducted at Taconic Biotechnology (1 University Place, Rensselaer NY 12144). Apolipoprotein E defi cient (ApoE-/-) mice were maintained under murine pathogen free barrier conditions for a duration of 40 weeks with continuous health monitoring, and manipulations were performed with IACUC approved procedures. Animals were fed with Chow diet and maintained at 12-hr light and 12-hr dark cycle. Three to four animals per cage (3 cages/ treatment group, 10 animals total) were housed in solid bottom polypropylene cages with sterilized bedding. At the age of 8 weeks, the mice were either kept on chow diet as control group or treated with ramipril or simvastatin. Ramipril was dissolved in sterilized drinking water and mice were fed at the dose of 5 mg/kg/day for 8, 16 and 24 weeks before sacrifi ce. Simvastatin was placed in chow diet, mice were fed at the dose of 50 mg/kg/day for 8, 16, 24 weeks before sacrifi ce. Weekly food and water consumption was recorded for each cage. Two batches of dosing experiments were conducted, one batch of mice were sacrifi ced for RNA analyses, whereas another batch for protein analysis.
Blood was collected via cardiac puncture procedure. 250 µl of the whole blood was placed directly into the RNA lysis buffer-containing tubes provided by the Source Precision Medicine and frozen. 200 µl of blood was placed in citrate tubes, and plasma was used for protein and lipid analysis.
Immediately following the blood collection, mice were perfused with saline and then IHC Zink fi xative via left ventricle. Brachiocephalic artery was dissected, fi xed in IHC Zink fi xative and paraffi n embedded. Histology 10 equally spaced (200 µm) paraffi n cross sections of the brachiocephalic artery were stained using hematoxylin and eosin. Macrophages and SMC were visualized immunohistochemically using MAC-2 (Accurate Chemical, Westbury, NY) and anti-α-smooth muscle actin antibody (DAKO) respectively. The lesion, defi ned as an area between the lumen and internal elastic lamina (IEL) was calculated using Image-Pro Plus Version 5.0.1
Blood analysis
Plasma lipids were analyzed on a Hitachi 912 clinical chemistry analyzer. Total and differential blood cell count was performed by the LabCorps. Quantifi cation of RNA expression. Two hundred fi fty µl of whole blood from each animal were sent to Source Precision Medicine (Boulder, CO). Expression of blood mRNA was quantifi ed using its proprietary precision technology (a modifi ed ∆∆CT method) with its validated rodent primers of ABCA1, CD14, HMOX1, HSPA1A, ILLRN, MMP-9, TGFβ1, TLR4, TNFSF5.
Immunoassay of plasma infl ammation markers.
Fifty µl of plasma from each animal were sent to Rules Based Medicine (Austin, TX) and were profi led using its proprietary multiplex assay platform with multiple analyte panel (MAP) version 1.5. The MAP contains 59 molecules.
Data analysis
Statistical analyses and pattern analyses were performed on SAS, JMP (SAS Institute, NC), MatLab (The MathWorks, MA) and Microsoft Excel.
Results
Atherosclerotic plaques developed over time, drug treatment either promoted or repressed atherogenesis
At the age of 8 weeks, ApoE-/-mice were treated continuously with angiotensin-II converting enzyme inhibitor ramipril, or HMG-CoA reductase inhibitor simvastatin, or by Chow diet alone for 8, 16 and 24 weeks before sacrifi ce. Figure 1a showed that plaque developed steadily from 8 weeks to 32 weeks in ApoE-/-mice fed with Chow diet. Ramipril treatment signifi cantly reduced the size of plaques compared to the Chow fed mice in all time points sampled (plaque size reduced 55.6%, 31.9% and 28.9% in 8, 16, 24 week treatments with p values of 0.005, 0.027 and 0.004, respectively. Fig. 1b, 1c and 1d ); on the contrary, simvastatin increased the atherosclerotic plaques compared to the chow fed mice (plaque size increased 3.0, 2.48 or 1.8 folds respectively, with p values of 0.001). Both treatments had no signifi cant effects on plasma cholesterol ( Fig. 2 and Table 1a ). Ramipril did not alter the concentration of triglycerids, whereas simvastatin signifi cantly reduced the triglyceride concentration ( Fig. 2 and Table 1b ).
Expression of CD14, IL1RN and MMP-9 RNA in whole blood correlated with the effect of ramipril and simvastatin on plaque size Expression of nine genes was measured in whole blood of ApoE -/-mice. These RNA were chosen because of available validated rodent primers by Source Precision Medicine (Boulder, CO). Signifi cant differences in expression of CD14, IL1RN and MMP-9 were observed between simvastatin-treated and ramipril-treated ApoE-/mice ( Fig. 3 a-c). Compared to those in the Chowfed animals, expression of these molecules increased in simvastatin-treated animals whose plaque sizes signifi cantly increased over controls. In contrast, expression of these molecules decreased in ramipril-treated animals ( Fig. 3 a-c) whose plaque size was signifi cantly reduced compared to the Chow-fed controls. The data suggest that CD14, IL1RN and MMP-9 are good biochemical markers of drug effects on atherosclerotic lesion size. Furthermore, the difference in markers can be measured as early as 8 weeks after the beginning of drug treatment ( Fig. 3a ).
Concentration of pro-infl ammatory molecules fi brinogen, IL-1b, IL-18, M-CSF, MMP-9, CD40 and VCAM-1 in plasma correlated with the effect of ramipril and simvastatin on plaque size.
Plasma samples were analyzed on multiplex assay platform (MAP version 1.5) by Rules Based Medicine (Austin, TX). These molecules and platform were chosen because of available validated rodent antibodies by RBM. Out of 59 molecules analyzed, the concentration of IL-1b, IL-18, M-CSF, MMP-9, CD40 and VCAM-1 increased in simvastatin-treated mice, decreased in ramipril-treated mice ( Fig. 4 , Appendix). Furthermore, the changes of these molecules in simvastatin-treated mice comparing to the controls are much more profound than the changes in ramipril-treated mice comparing to the controls. The result suggests that these molecules are potential biomarkers of drug effects on atherosclerotic lesion size, at least in the case of pro-atherogenic changes. The difference in the concentration of markers can be measured as early as 16 weeks after the beginning of drug treatment for IL-1b and MMP-9; all can be measured at 24 weeks after the beginning of drug treatment ( Fig. 4 ). No difference in white blood cell number among different treatment groups.
Cholesterol Level In ApoE-/-Mice
To dissect if the difference in gene expression and concentration of protein markers were affected by the cell number change, number of white blood cell from all treatment groups was counted ( Table 2) , no statistically signifi cant difference among the groups were found.
Discussion
In this paper, we have identifi ed the non-lipid circulating biomarkers indicative of both anti-and pro-atherogenic drug effects. We treated ApoE-/-mice with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin. Ramipril significantly reduced the size of atherosclerotic plaques in brachiocephalic arteries, however simvastatin paradoxically stimulated atherogenesis. Both effects occurred without changes in plasma cholesterol. We decided to exploit this phenomenon and seek circulating markers of cholesterolindependent, drug-induced vascular changes in ApoE-defi cient mice. Blood and vascular samples were obtained from the same animals. In the whole blood RNA samples, expression of MMP9, CD14 and IL-1RN refl ected pro-and anti-atherogenic drug effects. In the plasma, several proteins, e.g. IL-1β, IL-18 and MMP9 followed similar trends while protein readout was less sensitive than RNA analysis.
Ramipril is the only ACE inhibitor that is currently approved for the prevention of cardiovascular events in high risk patients based on the results of the HOPE trial. 13 It was demonstrated that in the normotensive patients, cardiovascular benefi ts of ramipril are independent of its blood pressure lowering effects. 14 ACE inhibitors also do not have lipid-lowering properties. Experimental data strongly suggest that these effects of ACE inhibitors are mediated by their direct anti-infl ammatory activity that ameliorates pro-infl ammatory signaling of angiotensin II in the vasculature. 15 Specifically, ramipril attenuated atherosclerosis in ApoE-/-mice in a blood pressureand cholesterol-independent manner 10 while preventing macrophage activation. 9 In agreement with these data, we demonstrated that ramipril treatment signifi cantly reduced atherosclerotic plaque size in ApoE-/-mice. Moreover, we have identifi ed several blood markers that have changed accordingly. Statins, including simvastatin, have unequivocal effect on the reduction of cardiovascular and allcause mortality, and this is likely due to the reduction in cholesterol. 16 However, the data on statin effi cacy in ApoE-/-mice are controversial. 17 Sparrow et al. reported anti-infl ammatory and anti-atherosclerotic activities of simvastatin exerted without any changes of plasma lipids. 18 Short-term anti-infl ammatory effects are also documented in the study of Scalia et al. 19 However, several groups reported signifi cant elevation of plasma cholesterol associated with increased atherosclerotic burden 20 and plaque size 12 in the mice with spontaneous atherosclerosis or intimal hyperplasia induced by mechanical injury of the artery. 11 It is suggested that paradoxical plasma cholesterol elevation could be driven by formation of cholesterol-rich remnants in apoE-/-mice. 21 Overall, pro-atherogenic effects of simvastatin in these studies are assumed to be the consequence of cholesterol elevation.
Our results, however, demonstrated an increase in plaque size without signifi cant plasma cholesterol elevation. That suggests potential direct pro-atherogenic (likely pro-infl ammatory) vascular effects of the drug in this animal model. Albeit counter-intuitive, this mechanism is supported by the data obtained in cultured human monocyte-derived macrophages. Kiener et al. reported that simvastatin stimulated production of MCP-1, IL-8, IL-1β and TNF-α. 2 2 Lindholm and Nilsson recently demonstrated that simvastatin stimulated IL-1β secretion. 23 Simvastatin also exerted pro-infl ammatory effects in a mouse model of peritonitits. 22 Recently, direct pro-apoptotic effects of simvastatin in human endothelial cells have been demonstrated. 24 Thus, it is plausible that under certain experimental circumstances simvastatin may exhibit proinfl ammatory properties that in the clinic either do not occur or are counterbalanced by profound lipid lowering thereby providing ultimate therapeutic benefi ts. In the current study, we have not attempted detailed mechanistic analysis of simvastatin activity in ApoE-/-mice. Rather, we capitalized on the observation that its pro-atherogenic effects, regardless the mechanism, were associated with an upsurge of several blood infl ammation markers. Taken together, ramipril and simvastatin arms of the study demonstrated that the same set of circulating markers responded in coordinated manner to both anti-and pro-atherogenic, lipidindependent drug effects. Exact mechanistic links between vascular effects of these drugs and their effects on the circulating markers of infl ammation are unknown. Several possibilities and combinations thereof exist. Moreover, the genesis of blood RNA and protein markers is likely to be different.
Whole blood RNA represents gene expression of various circulating cell populations, predominantly white blood cells, although it is impossible to exclude a contribution of red blood cells and platelets. White blood cell count per se may be associated with atherosclerosis. 25 That phenomenon alone might be responsible for apparent changes in gene expression. Our data though demonstrated no drug effect on the white blood cell number. However, enrichment of specifi c leukocyte types may still account for the RNA changes. It has been shown that the rise in monocyte count is associated with plaque formation in humans 26 and in the Western diet-fed ApoE-/-mice. 27 In the current study, we have not detected any signifi cant changes in monocyte numbers. However, more detailed analysis of monocyte sub-populations is granted. Thus, our data suggest that both ramipril and simvastatin could exert effects on the gene expression rather than affect the cell number. It remains unclear whether the drugs directly affected gene expression in circulating cells or, alternatively, blood RNA changes were secondary to the vascular wall effects. This is a fundamental and yet unanswered question that demands future in-depth research. The answer will determine how blood RNA changes will be positioned, i.e. as pharmacodynamic markers of drug activity or as circulating markers refl ecting biology of atherosclerotic plaques.
Specific tissue sources of plasma protein changes are even less clear. MMPs and interleukins (the proteins that, according to our data, seem to be sensitive to ramipril and simvastatin treatment) could originate, among other tissues, in the liver, adipose tissue or atherosclerotic plaques themselves. Regardless the exact origin, however, they have potential to become useful markers assuming that described effects can be extended to the other drugs capable of modifying vascular wall.
Although only limited set of genes and proteins was analyzed, it is tempting to speculate about coordinated nature of identifi ed changes. Noticeable MMP9 dynamics (downward with ramipril and upward with simvastatin) was detected both at the level of blood RNA and plasma protein, suggestive of the multiple tissues response. MMP9 protein levels in the lesions and in plasma are associated with plaque development and rupture in human and mouse atherosclerosis. [28] [29] [30] Extending that knowledge to circulating cell RNA (far more sensitive readout in this study) and demonstration of drug effects further validates this marker and potentially increases it's utility. CD14 gene upregulation in circulating leukocytes is consistent with emerging role of innate immunity in atherosclerosis. 1 It is likely that plasma IL1 protein elevation refl ects one of the downstream effects of activated innate immunity signaling. IL-1RN upregulation, anti-infl ammatory by nature, may indicate a negative compensatory feedback response to IL-1 elevation. 31 In this case, an anti-infl ammatory gene may be paradoxically portrayed as a sensitive marker of infl ammation and/or atherosclerosis.
We had also attempted to use whole blood proteomic approach (data not shown). However, whole blood proteomics has yet to provide discriminatory power that was necessary to identify the changes in infl ammatory protein molecules. A detailed report on comparing the whole blood shotgun proteomics vs. targeted proteomics approaches will be presented elsewhere.
In aggregate, our data suggest that a set of inflammation-related markers, both at the level of circulating leukocyte activation and systemic response may be indicative of pro-and anti-atherogenic drug effects. Current study represents the fi rst step towards identifi cation of circulating markers refl ecting lipid-independent, disease-modifying drug effects. The number of compounds with different mechanism of action as well as candidate genes and proteins needs to be extended. If further validated, presented approach might be useful in early prediction of vascular effi cacy and/or potential vascular toxicity of investigational drugs. 
